Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Candel Therapeutics Inc. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and is located within a distinct art unit. The alignment of these figures suggests a specific effort in the company's current patent prosecution. In the field of Biotechnology & Pharmaceuticals, having a portfolio in an area can allow for a legal strategy tailored to a set of examiner expectations.
WILSON, MICHAEL C is the busiest examiner for this portfolio, holding the busiest examiner pending office action. Because the total number of pending actions is a value in the data, WILSON, MICHAEL C is the only examiner currently reviewing the company's active applications. This concentration is observed in portfolios with an active matter. For the practitioner, this means that the entirety of the company's current interaction with the patent office is mediated by WILSON, MICHAEL C. The data shows a prosecution landscape for Candel Therapeutics Inc. with no evidence of multiple art unit involvement or multiple examiner hurdles.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILSON, MICHAEL C | 1 | 41.5% | +17.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18760242 | METHODS OF CYTOTOXIC GENE THERAPY TO TREAT TUMORS | WILSON, MICHAEL C | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18760242 | METHODS OF CYTOTOXIC GENE THERAPY TO TREAT TUMORS | WILSON, MICHAEL C | 1638 | §102§112DP | Non-Final OA | — | Pending | Jul 01, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCandel Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael C Wilson has the most, with 1 of Candel Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
